Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...

The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment selection continue reshaping cancer diagnostics.

When your care team starts discussing treatment for head and neck cancer, you may hear the term PD-L1, which stands for programmed death-ligand 1. Testing for PD-L1 helps your oncologist determine ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America ® Holdings (LabCorp ®) (NYSE: LH) today announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 ...

Consistently, first-line trials of immune checkpoint inhibitors in combination with chemotherapy have demonstrated overall survival benefit for patients with metastatic gastroesophageal cancer.

NEWARK, Del., June 16, 2026 /PRNewswire/ -- The global PD-L1 Biomarker Testing Market is witnessing robust expansion as precision oncology, immunotherapy adoption, and biomarker-driven treatment ...